
Minimally invasive gastric cancer surgery in Korea — KLASS-validated technique, shorter recovery, and among the world's highest stomach cancer survival outcomes.
Quick Answer
| Procedure time | 2–4 hours (varies by extent of resection) |
|---|---|
| Anesthesia | General anesthesia |
| Hospital stay | 7–12 days (Korean tertiary center average) |
| Recommended stay in Korea | 3–5 weeks (including pre-op evaluation and post-op follow-up) |
| Recovery | Return to light activity in 3–4 weeks; full recovery 6–10 weeks |
| Typical cost in Korea | $8,000–$18,000 USD (all-in range, procedure-dependent) |
Laparoscopic gastrectomy for gastric cancer involves surgically removing part or all of the stomach — along with a defined margin of surrounding tissue and regional lymph nodes — using small keyhole incisions and a camera-guided instrument system.
The minimally invasive approach results in less intraoperative blood loss, reduced postoperative pain, and faster return to oral intake compared with traditional open surgery.
Korea has been at the forefront of refining this technique over the past two decades. Korean surgical teams, particularly at high-volume cancer centers in Seoul and Gangnam, routinely perform hundreds of laparoscopic gastrectomies per year, accumulating case volumes that are difficult to match outside East Asia.
The procedure encompasses two main approaches: distal gastrectomy (removing the lower portion of the stomach, most common for antral tumors) and total gastrectomy (removing the entire stomach, used for proximal or diffuse-type cancers).
Lymph node dissection — the D2 lymphadenectomy — is the Korean and Japanese standard and is associated with thorough staging and regional disease control.
Request an International Patient Center coordinator
Major Korean cancer hospitals in Seoul have dedicated international patient centers staffed with English-speaking medical coordinators. They can prepare itemized cost estimates, arrange visa support letters, and coordinate pre-op staging so you arrive with your workup largely complete — reducing your total time in Korea.

Candidacy for laparoscopic gastrectomy in Korea is determined by a multidisciplinary oncology team reviewing imaging, endoscopy, and pathology results.
Good candidates fit a clear profile. They typically have clinical stage I or II gastric adenocarcinoma (cT1–T3, limited nodal burden) or early gastric cancer (EGC) found on screening endoscopy, with no peritoneal seeding or distant metastasis on staging CT/PET.
They also need adequate cardiopulmonary reserve to tolerate general anesthesia and a BMI suitable for laparoscopic access, assessed per surgeon judgment.
Situations that may require open or alternative approaches: - T4b tumors invading adjacent structures - N2 bulky or matted lymphadenopathy - Prior abdominal surgery creating significant adhesions - Emergency presentation with perforation or hemorrhage
Korean guidelines (Korean Practice Guidelines for Gastric Cancer 2024) and NCCN both note that laparoscopic and robotic surgery are appropriate for EGC and selected advanced cases when performed by experienced surgeons. The treating team at the Korean center will confirm eligibility after reviewing all staging workup.
The surgical team begins with a general anesthetic induction. The abdomen is insufflated with carbon dioxide gas to create working space, and typically four to five small port incisions (each under 12 mm) are placed.
A high-definition laparoscope is inserted, and the surgeon uses articulated instruments to mobilize the stomach by dividing its ligamentous attachments and the blood supply systematically.
D2 lymphadenectomy — dissection of the regional lymph node stations around the celiac axis, left gastric artery, and hepatic artery — is performed concurrently. This is a defining feature of the Korean and Japanese approach and is considered oncologically superior to a limited (D1) dissection for most resectable gastric cancers.
The stomach is then divided at the planned resection margins using a laparoscopic stapler. For distal gastrectomy, a Billroth I, Billroth II, or Roux-en-Y reconstruction restores gastrointestinal continuity. For total gastrectomy, an esophagojejunostomy (Roux-en-Y) is fashioned.
A specimen retrieval bag is used to extract the resected tissue through a small extended incision. A drain is typically left near the anastomosis. Total operative time ranges from approximately 2 to 4 hours depending on resection extent and reconstruction type.

Recovery from laparoscopic gastrectomy in Korea follows a structured enhanced recovery after surgery (ERAS) protocol at most major centers.
Days 1–3 (In hospital, early post-op): - Nasogastric tube removed within 24–48 hours if no leak - Clear liquids introduced around post-op day 2–3 - Ambulation encouraged from day 1 - Pain managed with epidural or IV analgesia transitioning to oral medications
Days 4–10 (In hospital, advancing diet): - Soft diet progression under dietitian supervision - Drain removed if output is low and non-bilious - Average Korean tertiary hospital discharge is approximately post-op day 8–10
Weeks 2–3 (Recovery accommodation in Korea): - Most international patients remain in Seoul or Gangnam for outpatient follow-up - Wound checks, blood tests, and surgical review - Diet counseling for post-gastrectomy nutrition (small frequent meals, B12 and iron monitoring)
Weeks 4–6 (Return home and light activity): - Light walking and household activity typically resumed - No heavy lifting or strenuous exercise
Weeks 6–10 (Full recovery): - Most patients return to normal daily activities - Oncology team determines whether adjuvant chemotherapy is indicated based on final pathology - Long-term nutritional supplementation (B12, iron, calcium) is common after total gastrectomy

Korean gastric cancer surgery costs are substantially lower than comparable procedures in the United States or Western Europe, without a corresponding reduction in surgical or oncological quality.
A 2025 systematic review published in Frontiers in Public Health, analyzing Korean health insurance data, reported median total costs of approximately $8,225 USD for laparoscopic gastrectomy, with distal gastrectomy averaging around $6,485 USD.
For international patients paying out-of-pocket (not covered by Korean National Health Insurance), pricing at private or international patient wings of tertiary hospitals is higher.
All-in estimates typically range from $10,000–$18,000 USD depending on extent of resection (distal vs. total), choice of hospital tier, length of stay, and whether robotic assistance is used.
Robotic-assisted gastrectomy (da Vinci platform) is available at many Korean centers and carries a premium of roughly $3,000–$5,000 USD over standard laparoscopic technique.
Costs generally exclude: airfare and accommodation, pre-trip staging scans obtained abroad, post-discharge adjuvant chemotherapy, and interpreter services (though many top centers provide Korean-English medical interpreters).
Always request an itemized estimate from the hospital's international patient center before travel.
| Item | Typical Cost in Korea (USD) |
|---|---|
| Laparoscopic distal gastrectomy (D2) | $8,000–$13,000 |
| Laparoscopic total gastrectomy (D2) | $11,000–$18,000 |
| Robotic-assisted gastrectomy (add-on) | $3,000–$5,000 (additional) |
| Pre-op staging (CT, endoscopy, labs) | $800–$1,800 |
| Accommodation (3–5 weeks, serviced apt) | $1,500–$4,000 |
South Korea has one of the world's highest incidences of gastric cancer per capita, which has driven decades of specialized investment in surgical technique, screening infrastructure, and oncology research.
The country's National Cancer Screening Program for Gastric Cancer, launched in 1999 and expanded in 2002, means Korean surgeons routinely operate on early-stage disease — producing case volumes and surgical refinement that are rare globally.
The landmark KLASS (Korean Laparoscopic Gastrointestinal Surgery Study) trials — a series of multicenter prospective randomized controlled trials — generated the evidence base that led NCCN and other international guidelines to formally recognize laparoscopic distal gastrectomy as a standard treatment option for stage I gastric cancer.
According to the Korea Health Industry Development Institute (KHIDI), South Korea surpassed one million foreign patient visits for the first time in 2024, with cancer treatment among the top drivers of international patient inflow.
Hospitals in Seoul and Gangnam with dedicated international patient centers offer English-language coordination, Korean-certified translators, and visa letter support — reducing logistical barriers for patients traveling from Africa, the GCC, and Southeast Asia.
Cost is another practical factor: comparable procedures in the United States can cost three to five times more, while Korean hospitals maintain internationally comparable imaging, pathology, and intensive care infrastructure.
Key Takeaways
For stage I gastric cancer, phase 3 randomized controlled trials (KLASS-01 in Korea, JCOG0912 in Japan) confirmed that laparoscopic distal gastrectomy is non-inferior to open surgery in oncological outcomes. NCCN guidelines now list it as a standard option. For more advanced stages, eligibility depends on tumor characteristics and is assessed by the surgical team.
Most international patients plan a 3–5 week stay. Hospital discharge typically occurs around day 8–12 post-operatively, followed by 1–2 weeks of outpatient recovery and at least one surgical review visit before the medical team clears travel. Your specific timeline depends on recovery progress and whether any complications arise.
D2 lymphadenectomy refers to systematic removal of the perigastric lymph nodes plus the nodes along the major arterial branches supplying the stomach (left gastric, common hepatic, celiac, and splenic arteries). Korean and Japanese surgical guidelines treat D2 dissection as the standard for resectable gastric cancer. It provides more thorough staging and is associated with better regional disease control than the more limited D1 dissection.
Whether chemotherapy is recommended after surgery depends on the final pathological stage found in the resected specimen. Many patients with stage II or III disease receive adjuvant chemotherapy per Korean Practice Guidelines. The oncology team at the Korean center will discuss adjuvant options before you leave; ongoing chemotherapy is typically administered back in your home country with coordination between your Korean oncologist and local provider.
After partial gastrectomy (distal), dietary adjustments include smaller, more frequent meals and avoiding high-sugar foods to prevent dumping syndrome. After total gastrectomy, lifelong supplementation with vitamin B12, iron, and calcium is typically required because these nutrients are absorbed in parts of the stomach and small intestine affected by surgery. Korean hospitals provide dietitian counseling during the inpatient stay.
Yes, robotic-assisted gastrectomy (typically da Vinci platform) is available at many Korean tertiary cancer centers. A 2025 systematic review found robotic gastrectomy to be non-inferior to laparoscopic gastrectomy in surgical outcomes with fewer postoperative complications in some analyses, but it involves longer operative time and higher cost. Your surgeon will advise whether robotic or standard laparoscopic approach is more appropriate for your case.
Get matched with KAHF-accredited hospitals and receive a personalized treatment plan.
Typical Cost
$15000 - $35000
Duration
14 days
Success Rate
95%+
Accredited Hospitals
0+ Available
The information provided on this page about Laparoscopic Gastric Cancer Operation is for general educational and informational purposes only. It is not intended as, and should not be construed as, medical advice, diagnosis, or treatment recommendations.
Always seek the advice of a qualified healthcare professional regarding any medical condition or treatment. Never disregard professional medical advice or delay seeking it because of information found on this website. Individual treatment outcomes may vary. Costs shown are estimates and may differ based on individual circumstances.
KmedTour acts as a medical tourism facilitator and does not provide direct medical services. All treatments are performed by independently accredited healthcare providers in South Korea.